Guillain-Barré Syndrome Diagnosis and Treatment Strategies

Guillain-Barré syndrome (GBS) is an acute, immune-mediated neuropathy characterised by rapidly progressive limb weakness and areflexia. Diagnostic evaluation begins with a detailed clinical history, noting antecedent infections and the pattern of ascending motor impairment. Nerve conduction studies distinguish demyelinating from axonal subtypes, guiding prognosis and therapeutic choices. Cerebrospinal fluid analysis typically reveals albuminocytological dissociation, while emerging blood biomarkers such as neurofilament light chain and peripherin offer dynamic measures of axonal injury. Immunopathological studies have demonstrated both humoral and cellular autoreactivity against peripheral myelin and axonal antigens, reflecting a heterogeneous spectrum of immune mechanisms. First-line treatment comprises supportive care—often in an intensive care setting for ventilatory support—and immunotherapies, notably intravenous immunoglobulin (IVIg) or plasma exchange. Early intervention shortens disease course and reduces disability, yet a subset of patients experiences treatment refractoriness or delayed recovery. Advances in understanding T-cell and inflammasome-mediated pathways have prompted investigation of novel agents, including complement inhibitors and purinergic receptor antagonists. A multidisciplinary approach, integrating electrophysiology, biomarker monitoring and tailored immunomodulation, underpins contemporary management and informs the development of precision strategies for GBS.

Research from Nature Portfolio

Recent studies have delineated the cellular basis of immune attack in GBS by applying single-cell RNA sequencing and T-cell receptor profiling to patient blood, cerebrospinal fluid and nerve tissue. This work has identified polyclonal autoreactive CD4+ T cells with a TH1-like phenotype and rare CD8+ clones that recognise myelin epitopes, revealing shared clonotypes across patients and disease stages. These findings clarify the antigenic targets driving demyelination and support the design of epitope-specific immunotherapies. In parallel, a globally applicable clinical guideline has been proposed through a structured, ten-step framework encompassing early recognition, electrophysiological classification, treatment indications, monitoring of progression, prediction of outcome and management of complications. This comprehensive protocol harmonises diagnostic criteria and therapeutic decision-making in diverse healthcare settings, emphasising rapid initiation of IVIg or plasma exchange and standardising supportive measures to improve patient outcomes.

Guillain-Barré Syndrome Diagnosis and Treatment Strategies publication trend

The graph below shows the total number of articles in guillain-barré syndrome diagnosis and treatment strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Albuminocytological dissociation: Elevated cerebrospinal fluid protein with normal cell count.

Electrophysiological subtype: Classification based on nerve conduction studies into demyelinating or axonal forms.

Intravenous immunoglobulin (IVIg): Pooled antibody preparation used to modulate immune responses.

Neurofilament light chain (NfL): Axonal cytoskeletal protein released into blood after nerve injury.

Peripherin: Intermediate filament protein specific to peripheral nerve axons, serving as a damage biomarker.

Plasma exchange: Therapeutic removal of autoantibodies and inflammatory mediators from plasma.

Single-cell RNA sequencing: Technique for profiling gene expression in individual cells to identify pathogenic subsets.

T-cell receptor repertoire: Diversity of antigen-recognition sequences on T cells, reflecting specificity of immune responses.

References

1. Autoreactive T cells target peripheral nerves in Guillain–Barré syndrome. Nature (2024).
2. Peripherin is a biomarker of axonal damage in peripheral nervous system disease. Brain (2023).
3. Dynamics and prognostic value of serum neurofilament light chain in Guillain-Barré syndrome. EBioMedicine (2024).
4. P2X7 receptor antagonists modulate experimental autoimmune neuritis via regulation of NLRP3 inflammasome activation and Th17 and Th1 cell differentiation. Journal of Neuroinflammation (2024).
5. Diagnosis and management of Guillain–Barré syndrome in ten steps. Nature Reviews Neurology (2019).